Day One Biopharmaceuticals Inc’s recent filing unveils that its Chief Commercial Officer Merendino Lauren unloaded Company’s shares for reported $24575.0 on May 16 ’25. In the deal valued at $6.26 per share,3,927 shares were sold. As a result of this transaction, Merendino Lauren now holds 35,161 shares worth roughly $0.23 million.
Then, Dubow Adam sold 4,552 shares, generating $28,486 in total proceeds. Upon selling the shares at $6.26, the GENERAL COUNSEL now owns 47,136 shares.
Before that, York Charles N II sold 4,282 shares. Day One Biopharmaceuticals Inc shares valued at $26,796 were divested by the COO, CFO AND SECRETARY at a price of $6.26 per share. As a result of the transaction, York Charles N II now holds 265,231 shares, worth roughly $1.75 million.
Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy in a research note published on October 09, 2024; the price target was $33. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early August from “an Underperform” to “a Buy”. Needham also remained covering DAWN and reiterated its “Buy” recommendation on April 24, 2024. BofA Securities revised its rating on April 25, 2023. It rated DAWN as “an Underperform” which previously was an “a Buy”.
Price Performance Review of DAWN
On Tuesday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock jump 1.54% to $6.58. Over the last five days, the stock has gained 3.95%. Day One Biopharmaceuticals Inc shares have fallen nearly -48.07% since the year began. Nevertheless, the stocks have fallen -58.95% over the past one year. While a 52-week high of $16.76 was reached on 01/28/25, a 52-week low of $6.08 was recorded on 05/16/25. SMA at 50 days reached $7.46, while 200 days put it at $11.77.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 6.44, which if violated will result in even more drops to 6.31. On the upside, there is a resistance level at 6.66. A further resistance level may holdings at 6.75. The Relative Strength Index (RSI) on the 14-day chart is 43.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.12%. Stochastics %K at 17.74% indicates the stock is a buying.
The most recent change occurred on February 08, 2023 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
